FCX-007 not checked
Castle Creek Biosciences, LLC.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.”In the company’s words, NCT04213261 on ClinicalTrials.gov
- Main trialPhase 3
- “The purpose of this study is to determine whether administration of FCX-007 in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Recessive Dystrophic Epidermolysis Bullosa. Funding Source - FDA OOPD”In the company’s words, NCT04213261 on ClinicalTrials.gov
Other drugs for Recessive Dystrophic Epidermolysis Bullosa
- KB803Krystal Biotech, Inc. · Phase 3
- D-FiCastle Creek Biosciences, LLC. · Phase 3
- Oleogel-S10Chiesi Farmaceutici S.p.A. · Phase 3
- ENERGI-F703Energenesis Biomedical Co., Ltd. · Phase 2
- TCP-25 gelXinnate AB · Phase 2
- AGLE-102Aegle Therapeutics · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 17 Jan 2023 | A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026